These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11941814)

  • 1. [Tumor necrosis factor modulators in the treatment of rheumatoid arthritis].
    Konttinen YT; Valleala H; Honkanen V; Törnwall J; Tensing EK; Sorsa T; Nordström D
    Duodecim; 1999; 115(18):1969-76. PubMed ID: 11941814
    [No Abstract]   [Full Text] [Related]  

  • 2. [New drug treatments for rheumatoid arthritis].
    Nordström DC; Konttinen YT
    Duodecim; 2000; 116(11):1221-5. PubMed ID: 11989008
    [No Abstract]   [Full Text] [Related]  

  • 3. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.
    Fleischmann R; Shealy D
    Mol Interv; 2003 Sep; 3(6):310-8. PubMed ID: 14993463
    [No Abstract]   [Full Text] [Related]  

  • 4. [Blockade of TNFalpha--new therapeutic principle in severe rheumatoid arthritis].
    Larsson P; Bratt J; Harju A; van Vollenhoven R; Klareskog L
    Lakartidningen; 2001 Feb; 98(8):828-31. PubMed ID: 11265568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-TNF revolution in ankylosing spondylitis: patients with severe disease now have access to promising new drugs.
    Schachna L
    Med J Aust; 2004 Nov; 181(10):529-30. PubMed ID: 15540959
    [No Abstract]   [Full Text] [Related]  

  • 6. TNF receptor fusion protein in rheumatoid arthritis.
    O'Brien C
    Mol Med Today; 1996 Jul; 2(7):269. PubMed ID: 8796900
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism.
    Chatzikyriakidou A; Georgiou I; Voulgari PV; Venetsanopoulou AI; Drosos AA
    Rheumatology (Oxford); 2007 Jun; 46(6):1034-5. PubMed ID: 17409133
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 10. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
    Berg PA
    Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor necrosis factor alpha haplotypes versus tumor necrosis factor alpha -308 G/A polymorphism in the prediction of infliximab treatment efficacy in rheumatoid arthritis.
    Mugnier B; Roudier J
    Arthritis Rheum; 2004 Dec; 50(12):4075-6; author reply 4076-7. PubMed ID: 15593229
    [No Abstract]   [Full Text] [Related]  

  • 12. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
    Kaplan MJ
    Nat Clin Pract Rheumatol; 2005 Dec; 1(2):74-5. PubMed ID: 16932633
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
    Mizutani W
    Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis.
    di Comite G; Marinosci A; Di Matteo P; Manfredi A; Rovere-Querini P; Baldissera E; Aiello P; Corti A; Sabbadini MG
    Ann N Y Acad Sci; 2006 Jun; 1069():428-37. PubMed ID: 16855170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of tumor necrosis factor inhibitors in patients with RA.
    Trethewey P
    JAAPA; 2002 Sep; 15(9):23-4, 27, 30 passim. PubMed ID: 12395668
    [No Abstract]   [Full Text] [Related]  

  • 16. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy.
    Gómez-Puerta JA; Sanmartí R; Rodríguez-Cros JR; Cañete JD
    Ann Rheum Dis; 2004 Jul; 63(7):896. PubMed ID: 15194598
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of rheumatoid arthritis with a tumor necrosis factor receptor-Fc fusion protein.
    Mannik M; Wener M
    N Engl J Med; 1997 Nov; 337(21):1560; author reply 1560-1. PubMed ID: 9380131
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
    Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
    Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination therapy with biologic agents in rheumatoid arthritis: perils and promise.
    Kremer JM
    Arthritis Rheum; 1998 Sep; 41(9):1548-51. PubMed ID: 9751086
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.